Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Keywords
- Breast Cancer
- Epidermal Growth Factor Receptor
- Human Epidermal Growth Factor Receptor
- Clin Oncol
- Metastatic Breast Cancer
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Jemal A, Murray T, Samuels A et al: Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26
Chia, SK, Speers, C, Kang, A, et al. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer in a population based cohort (abstract). Proc Am Soc Clin Oncol. 2003; 22:6a
Beatson, GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2:104
Osborne CK; Yochmowitz MG; Knight WA 3rd; McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980; 46(12 Suppl):2884–8
Wells A. EGF receptor. Int J Biochem Cell Biol. 1999; 31:637–643
6-Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312:513–516
Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19: 3159–3167
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235:177–182
Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990; 61: 203–212
Garus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997; 16:1647–1655
Segatto O, Lonardo F, Pierce JH, Bottaro DP, Di Fiore PP. The role of autophosphorylation in modulation of erbB-2 transforming function. New Biol. 1990; 2: 187–195
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16: 5276–5287
Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, Clinton GM. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998; 58: 5123–5129
Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001; 61: 4744–4749
Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001; 28:4–11
Yip YL, Ward RL. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother 2002; 50:569–587
Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197–205
Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9:1829–38
Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998; 17:2235–49
Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241–51
Konecny G, Pegram MD, Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res Treat 1999; 57:114
Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999; 59:1347–55
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825–31
Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L, Wolter J, Paton V, Shak S, Lieberman G, Slamon D. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639–2648
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1997; 17:1983–1987
Baselga, J. Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials. Oncology 2001; 61(Suppl.2):14–21
Bell, R. What Can We Learn from Herceptin® Trials in Metastatic Breast Cancer? Oncology 2002; 63(Suppl.1):39–46
Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. NEngl J Med 2001; 344:783–792
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L,. Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. J Clin Oncol 2002; 20:719–726
Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander, Jr. RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm. J Clin Oncol 2003; 21:2889–2895
Meden H, Beneke A, Hesse T, et al. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res. 2001; 21:1301–1305
Burris HA 3rd. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol. 2001; 28(1 suppl 3):38–44
Kuzur M, Albain K, Huntngton M, et al. A phase II trial of docetaxel and herceptin in metastatic breast cancer patients overexpressing HER2. Program and abstracts of the 36th Annual Meeting of the American Society of Clinical Oncology; May 20–23, 2000; San Francisco. Abstract 512
Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-pl85HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998; 16:2659–2671
O'Shaughnessy J, Vukelja SJ, Marsland T, et al. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin Breast Cancer. 2002; 3(suppl 1): 17–20
Miller K, Sisk J, Ansari R, et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt). 2001;15(2 suppl 3):38–40
Robert N, Slamon D, Leyland J, et al. Toxicity profiles: a comparative study of Herceptin and taxol vs. Herceptin, taxol, and carboplatin in HER2+ patients with advanced breast cancer. Program and abstracts of the 24th Annual San Antonio Breast Cancer Symposium; December 10–13, 2001; San Antonio, Texas. Abstract 529
Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel. J Clin Oncol 2003; 21:3965–3971
Carbonell Castellon X, Castaneda-Soto N, Clemens M, et al. Efficacy and safety of 3-weekly Herceptin monotherapy in women with HER2+ metastatic breast cancer: preliminary data from a phase II study. Program and abstracts of the 38th Annual Meeting of the American Society of Clinical Oncology; May 18–22, 2002; Orlando, Florida. Abstract 73
Tripathy D, Slamon D, Leyland-Jones B, et al. Treatment beyond progression in the Herceptin pivotal combination chemotherapy trial. Breast Cancer Res Treat. 2000; 64:32. Abstract 25
Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003; 4(2):120–5
Tan AR, Swain SM. Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol. 2003; 30(5 Suppl 16):54–64.
Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37Suppl 4:S3–8
Todd R, Wong DT. Epidermal growth factor receptor (EGFR) biology and human oral cancer. Histol Histopathol 1999; 14:491–500
Mendrola JM, Berger MB, King MC, Lemmon MA. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem 2002; 277:4704–12
Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19(18 Suppl):32S–40S
Shoelson SE. SH2 and PTB domain interactions in tyrosine kinase signal transduction. Curr Opin Chem Biol 1997; 1:227–34
Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001;12:397–408
Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905–27
Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211–25
D'Errico A, Barozzi C, Fiorentino M, Carella R, Di Simone M, Ferruzzi L, et al. Role and new perspectives of transforming growth factor-alpha (TGF-alpha) in adenocarcinoma of the gastro-oesophageal junction. Br J Cancer 2000; 82:865–70
Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37Suppl 4:S9–15
Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990; 50:8017–22
Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996; 13:85–96
Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998; 273:200–6
Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55:5536–9
Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL, Foekens JA. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10-year follow-up study. Breast Cancer Res Treat 1994; 29: 73–83
Sharma AK, Horgan K, Douglas-Jones A, McClelland R, Gee J, Nicholson R. Dual immunocytochemical analysis of estrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer 1994; 69: 1032–7
Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW. Transforming growth factor-alpha and endocrine sensitivity in breast cancer. Cancer Res 1994; 54:1684–9
Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW. Relationship between EGF-R. c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 7:1018–23
Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989; 34:123–31
Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL. Inhibition of HER2/neu (erbB2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60:5887–94
Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, Doihara H, Shimizu N, Sonoo H. Anti-HER2 antibody enhances the growth inhibitory effect of anti-estrogen on breast cancer cells expressing both estrogen receptors and HER2. Br J Cancer 2000; 82:46–51
Massarweh S, Shou J, Mohsin SK, Ge M, Wakeling A, Osborne CK, Schiff R. Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 (“IRESSA”) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors. Proc Am Soc Clin Oncol 2002; 21:33a
Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (IRESSA) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61: 8887–95
Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44:1002–1007
Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958–70
Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor stimulated tyrosine protein kinase activity. J Biol Chem 1984; 259:7755–60
Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000;82:1991–9
Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:1935–40
Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S, et al. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin Cancer Res 1999; 5:875–81
Kawamoto T, Sato JD, Le A, et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA. 1983; 80:1337–1341
Sato JD, Kawamoto T, Le AD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983; 1:511–529
Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904–914
Hong WK, Arquette M, Nabell L, et al. Efficacy and safety of the anti-epidermal growth factor antibody IMC-225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Program and abstracts of the 37th Annual Meeting of the American Society of Clinical Oncology; May 12–15, 2001; San Francisco, California. Abstract 895
Kim ES, Mauer A, Fosella FV, et al. A phase II trial of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. Program and abstracts of the 38th Annual Meeting of the American Society of Clinical Oncology; May 18–22, 2002; Orlando, Florida. Abstract 1165
Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor. Program and abstracts of the 37th Annual Meeting of the American Society of Clinical Oncology; May 12–15, 2001; San Francisco, California. Abstract 7
Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol. 2003;22:252. Abstract 1012.
Burtness BA, Li Y, Flood W, et al. Phase III trial comparing cisplatin + placebo to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients with metastatic recurrent head & neck cancer. Program and abstracts of the 38th Annual Meeting of the American Society of Clinical Oncology; May 18–22, 2002; Orlando, Florida. Abstract 901
Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002; 20(18 suppl): 1S–13S
Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 1999; 54:739–748
Iwata KK, Provoncha K, Gibson N. Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva) [Abstract No. 79]. Proc ASCO 2002;21
Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001; 19:3267–3279
Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2001; 20:310a. Abstract 1235.
Finkler N, Gordon A, Crozier M, et al. Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol. 2001; 20:208a. Abstract 831
Senzer NN, Soulieres D, Siu L, et al. Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 2001; 20:2a. Abstract 6
Clark GM, Perez-Soler R, Siu L, et al. Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol. 2003; 22:196. Abstract 786
Pedersen MW, Meltom M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol. 2001; 12:745–760
Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD 1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002; 20:4292–4302
Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002;20:3815–3825
Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002; 20:2240–2250
Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003; 21:2237–2246
Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290:2149–2158
Giaccone G, Johnson D, Manegold C, et al. A phase III clinical trial of ZD1839 ('IRESSA') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol. 2002; 13(suppl 5):2. Abstract 40
Johnson DH, Herbst R, Giaccone G, et al. ZD1839 ('IRESSA') in combination with paclitaxel & carboplatin in chemotherapy naive patients with advanced non-small cell lung cancer (NSCLC): results from a phase III trial (INTACT 2). Ann Oncol. 2002; 13(suppl 5):127. Abstract 4680
Normanno N, Campiglio M, De Luca A et al. Cooperative inhibitory effect of ZD1839 (IRESSA) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002; 13:65–72
Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (IRESSA), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001; 94:774–82
Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, Ciardiello F, et al. Cooperative inhibitory effect of ZD1839 (IRESSA) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002; 13:65–72
Burris HA, Taylor C, Jones S, et al. A phase I study of GW572016 in patients with solid tumors. Proc Am Soc Clin Oncol. 2003; 22:248. Abstract 994
Belanger M, Jones CM, Germond C, et al. A phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU in combination with irinotecan and/or oxaliplatin. Proc Am Soc Clin Oncol. 2003; 22:244. Abstract 978
Gasparini G. Angiogenesis in breast cancer role in biology tumor progression and prognosis. Breast Cancer: Molecular Genetics Pathogenesis and Therapeutics. Totowa, NJ: Humana Press Inc; 1999:347–371
Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362:841–844
Warren RS, Yuan H, Matli MR, et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995; 95:1789–1797
Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19:843–850
Sledge G, Miller K, Novotny W, et al. Phase II trial of single agent rhuMab VEGF in patients with relapsed metastatic breast cancer. Program and abstracts of the 36th Annual Meeting of the American Society of Clinical Oncology; May 20–23, 2000; San Francisco, California. Abstract 5C
Hurwitz H, FL FL, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol. 2003; 22. Abstract 3646
Miller KD, Rugo H, Cobleigh MA, et al. Phase III trial of capecitabine plus bevacizumab versus capecitabine alone in women with metastatic breast cancer previously treated with an anthracycline and a taxane. Breast Cancer Res Treat. 2002; 76(suppl 1):S37
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Mayer, I.A. (2005). Targeting Cytokine Receptors and Pathways in the Treatment of Breast Cancer. In: Platanias, L.C. (eds) Cytokines and Cancer. Cancer Treatment and Research, vol 126. Springer, Boston, MA. https://doi.org/10.1007/0-387-24361-5_10
Download citation
DOI: https://doi.org/10.1007/0-387-24361-5_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24360-3
Online ISBN: 978-0-387-24361-0
eBook Packages: MedicineMedicine (R0)